Aperçu

Éligibilité

Détails de la conception

Bras et interventions

Mesures des résultats

Sites d'essai

Source : NCT06281405

Recrutement en cours

TORCH-iTNT: CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

Interventionnel

Phase 2

Fudan University Shanghai Cancer Center

Sponsor: Fudan University

Dernière synchronisation : 3 avril 2026
Avis - Les informations proviennent de registres publics et peuvent ne pas refléter les changements en temps réel sur le site local.

TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1). Group A receives 6 cycles of Toripalimab combined with CAPOX (ToriCAPOX). Group B receives SCRT (25Gy/5Fx) followed by 6 cycles of ToriCAPOX. TME surgery is scheduled after TNT while a watch and wait (W&W) option can be applied to patients achieving clinical complete response (cCR). The primary endpoint is complete response (CR, pathological complete response [pCR] plus cCR) rate. The secondary endpoints include the grade 3-4 acute adverse effects (AE) rate, organ or anal preservation rate, 3-year DFS rate, etc.

Catégorie de traitement

Chimiothérapie, Radiothérapie, Autres médicaments

Mutations requises

Aucun

Essai commencé

28 mars 2024

Dernière mise à jour par le sponsor

3 avril 2026

Achèvement estimé

30 juin 2026

Contact de l'étude

Nom:Zhen Zhang, MD

E-mail:zhen_zhang@fudan.edu.cn

Téléphone:18801735029

Nom:Yaqi Wang, MD

E-mail:10301010093@fudan.edu.cn

Téléphone:18121299593

Éligibilité

Critères d'inclusion

1. Age 18-70 years old, female and male;

2. Pathological confirmed adenocarcinoma;

3. The distance from anal verge ≤ 10 cm;

4. MSI/MMR status: MSS/pMMR;

5. Clinical stage T3-4 and/or N+, without distance metastases;

6. At least one of the following factors is present: distance from the anus ≤5 cm, cT4, cN2, positive cMRF, positive cEMVI, or positive lateral lymph nodes;

7. KPS ≥ 70;

8. No radiotherapy, chemotherapy, immunotherapy, or any other anti-tumor therapy had been administered prior to enrollment;

9. Baseline blood and biochemical indicators meet the following criteria: neutrophils ≥ 1.5 × 10^9/L, Hb ≥ 90 g/L, PLT ≥ 100 × 10^9/L, ALT/ AST ≤ 2.5 ULN, Cr ≤ 1 ULN;

10. With good compliance and signed the consent form.

Critères d'exclusion

1. Pregnancy or breast-feeding women;

2. Known history of other malignancies within 5 years;

3. Known history of severe neurological or mental illness (such as schizophrenia, dementia or epilepsy);

4. Current severe cardiac disease (cardiac dysfunction and arrhythmia), renal dysfunction and liver dysfunction;

5. Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment;

6. Uncontrolled infection which needs systemic therapy;

7. Active autoimmune disease or immunodeficiencies, known history of organ transplantation or systematic use of immunosuppressive agents;

8. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1 to 2 antibody positive), active syphilis infection, active pulmonary tuberculosis infection;

9. Allergic to any component of the therapy.

Pensez-vous que cet essai apparaît incorrectement ?

Détails de la conception

AllocationRandomized

Modèle d'interventionParallel Assignment

MasquageNone (Open Label)

Nombre à inscrire192

Bras et interventions

Bras

Interventions

Type : Experimental

Description : The patients will receive 6 cycles of CAPOX and PD-1 antibody. TME surgery is scheduled after TNT while a W&W option can be applied to patients achieving cCR.

Interventions :

Capecitabine
Short-course radiotherapy
PD-1 inhibitor
Oxaliplatin

Mesures des résultats

Mesures des résultats primaires

Complete response (CR) rate1 month after the surgery or the decision of W&W

Rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W&W strategy.

Mesures des résultats secondaires

3 year disease free survival rateFrom date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.

Rate of 3 year disease free survival

3 year local recurrence free survival rateFrom date of randomization until the date of first documented pelvic failure, assessed up to 36 months.

Rate of 3 year local recurrence free survival

3 year overall survival rateFrom date of randomization until the date of death from any cause, assessed up to 36 months.

Rate of 3 year overall survival

Grade 3-4 adverse effects rateFrom date of randomization until 3 months after the completion neoadjuvant therapy

Rate of chemotherapy, radiotherapy and immunotherapy related adverse events

Rate of surgical complicationsThe surgical complications were assessed within 3 months after the surgery.

Rate of surgical complications, such as intraoperative hemorrhage, anastomotic leakage, intestinal obstruction, etc.

3 year organ or anal preservation rateFrom date of randomization until the resection of rectum or anus, assessed up to 36 months.

3 year organ or anal preservation rate

3 year distant metastasis free survival rateFrom date of randomization until the date of first documented distant metastasis, assessed up to 36 months.

Rate of 3 year distant metastasis free survival

Mettre l'essai en favori

Partager l'essai

Télécharger l'essai

Pensez-vous que cet essai apparaît incorrectement ?

Signaler l'essai

Télécharger l'essai

Sites d'essai

Cette étude compte 1 site d'essai

Fudan University Shanghai Cancer Center

Shanghai, CN

Nom:Zhen Zhang, MD, PHD

E-mail:zhen_zhang@fudan.edu.cn

Téléphone:18801735029

Recrutement en cours

Shanghai, CN

Fudan University Shanghai Cancer Center

Loading Maps...